Neurogene Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Neurogene Inc. (NGNE) reported Increase (Decrease) in Prepaid Expense and Other Assets of $774.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$34.00K, a 105.07% decline year-over-year.
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $808.00K, a 190.65% increase year-over-year.
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$2.32M.
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $417.00K.
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$952.00K, a 391.13% decline from fiscal 2024.
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $327.00K.
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$326.00K.
- Neurogene Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$716.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 123 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $774.00K 10-Q · filed 2026-08-11 | -$1.54M derived: sum of 3 quarters · filed 2026-08-11 | -$1.13M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2026-03-31 | $808.00K 10-Q · filed 2026-05-12 | -$1.51M derived: sum of 2 quarters · filed 2026-05-12 | -$1.09M derived: sum of 3 quarters · filed 2026-05-12 | -$422.00K derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-12-31 | -$2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$1.90M derived: sum of 2 quarters · filed 2026-03-24 | -$1.23M derived: sum of 3 quarters · filed 2026-08-11 | -$952.00K 10-K · filed 2026-03-24 | |||||
| 2025-09-30 | $417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.09M derived: sum of 2 quarters · filed 2026-08-11 | $1.37M 10-Q · filed 2025-11-13 | $239.00K derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-06-30 | $671.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $949.00K 10-Q · filed 2026-08-11 | -$178.00K derived: sum of 3 quarters · filed 2026-08-11 | -$777.00K derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-03-31 | $278.00K 10-Q · filed 2026-05-12 | -$849.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.45M derived: sum of 3 quarters · filed 2026-05-12 | -$812.00K derived: sum of 4 quarters · filed 2026-05-12 | |||||
| 2024-12-31 | -$1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$1.73M derived: sum of 2 quarters · filed 2026-03-24 | -$1.09M derived: sum of 3 quarters · filed 2026-03-24 | $327.00K 10-K · filed 2026-03-24 | |||||
| 2024-09-30 | -$599.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $37.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.45M 10-Q · filed 2025-11-13 | $258.00K derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.05M 10-Q · filed 2025-08-11 | $857.00K derived: sum of 3 quarters · filed 2025-08-11 | $1.09M derived: sum of 4 quarters · filed 2025-08-11 | |||||
| 2024-03-31 | $1.42M 10-Q · filed 2025-05-09 | $221.00K derived: sum of 2 quarters · filed 2025-05-09 | $457.00K derived: sum of 3 quarters · filed 2025-05-09 | $311.00K derived: sum of 4 quarters · filed 2025-05-09 | |||||
| 2023-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$960.00K derived: sum of 2 quarters · filed 2025-03-24 | -$1.11M derived: sum of 3 quarters · filed 2025-03-24 | -$326.00K 10-K · filed 2025-03-24 | |||||
| 2023-09-30 | $236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $90.00K derived: sum of 2 quarters · filed 2024-11-18 | $870.00K 10-Q · filed 2024-11-18 | ||||||
| 2023-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $634.00K 10-Q · filed 2024-08-09 | |||||||
| 2023-03-31 | $780.00K 10-Q · filed 2024-05-10 | ||||||||
| 2022-12-31 | -$716.00K 10-K · filed 2024-03-18 | ||||||||
| 2015-12-31 | -$234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$308.00K derived: sum of 2 quarters · filed 2016-03-14 | -$276.00K derived: sum of 3 quarters · filed 2016-03-14 | $130.00K 10-K · filed 2016-03-14 | |||||
| 2015-09-30 | -$74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$42.00K derived: sum of 2 quarters · filed 2015-11-10 | $364.00K 10-Q · filed 2015-11-10 | $219.00K derived: sum of 4 quarters · filed 2016-03-14 | |||||
| 2015-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $438.00K 10-Q · filed 2015-08-06 | $293.00K derived: sum of 3 quarters · filed 2016-03-14 | $150.00K derived: sum of 4 quarters · filed 2016-03-14 | |||||
| 2015-03-31 | $406.00K 10-Q · filed 2015-05-12 | $261.00K derived: sum of 2 quarters · filed 2016-03-14 | $118.00K derived: sum of 3 quarters · filed 2016-03-14 | -$67.33K derived: sum of 4 quarters · filed 2016-03-14 | |||||
| 2014-12-31 | -$145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$288.00K derived: sum of 2 quarters · filed 2016-03-14 | -$473.33K derived: sum of 3 quarters · filed 2016-03-14 | -$20.00K 10-K · filed 2016-03-14 | -$20.23K 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | -$143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$328.33K derived: sum of 2 quarters · filed 2015-11-10 | $125.00K 10-Q · filed 2015-11-10 | $125.08K 10-Q · filed 2014-11-04 | $191.86K derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-06-30 | -$185.34K 10-Q · filed 2014-08-11 | $268.00K 10-Q · filed 2015-08-06 | $268.37K 10-Q · filed 2014-08-11 | $334.86K derived: sum of 3 quarters · filed 2016-03-14 | $372.72K derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-03-31 | $454.00K 10-Q · filed 2015-05-12 | $453.70K 10-Q · filed 2014-05-13 | $520.20K derived: sum of 2 quarters · filed 2016-03-14 | $558.06K derived: sum of 3 quarters · filed 2016-03-14 | $566.48K derived: sum of 4 quarters · filed 2016-03-14 | $626.22K 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | $66.20K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $104.06K derived: sum of 2 quarters · filed 2016-03-14 | $112.48K derived: sum of 3 quarters · filed 2016-03-14 | $102.00K 10-K · filed 2016-03-14 | $102.79K 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | $37.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $46.28K derived: sum of 2 quarters · filed 2014-11-04 | $35.80K 10-Q · filed 2014-11-04 | ||||||
| 2013-06-30 | $8.42K 10-Q · filed 2014-08-11 | -$2.06K 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | -$10.48K 10-Q · filed 2014-05-13 | ||||||||
| 2012-12-31 | $12.08K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |